Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agreed. He has some great experience. The next 6 months are absolutely critical and hope he has what it takes to manage us through the big bump that’s coming.
Was before Lannett cancellation. We’ll see what happens to R&D over next couple quarters.
The hype is endless.
The CEO has already had to push back profitability. That is not under promising and over delivering.
No, Elon Musk will not be rolling this into Space X and the assumption of $1B buyout is simply a rumor. No one knows the offer and whether it was even official. Lots of rumors with no substance.
Lots of hype that needs to materialize into substance over time. Growth is good year/year, but it’s the law of small numbers at this point.
Until profitability tracks to expectations and CFP is reached, there are concerns around viability and liquidity. I am expecting a round of equity raise next year will be needed. Cash burn is too high and profitability targets have been pushed out. Stock will get to ans certainly surpass $10, but not in 2022. There are no near term drivers to get us anywhere close to that. They have a good handle on revenue pipeline for the next 6 months so there will be no significant top line surprises.
Entering automotive and tooling markets. Shipping expected to start Q4. High demand already for use with new approved material:
https://www.otcdynamics.com/vld-velo3d-qualifies-m300-tool-steel-for-use-in-its-sapphire-family-of-printers/?utm_campaign=twitter&utm_medium=twitter&utm_source=twitter
Flying solo on sales/marketing.
Relisten to Q4 cc “So I am not expecting anything is going to happen for at least six months, if we are lucky, okay.” This at least puts us into next year.
Q1 cc in AUg referred to updates in future CALLS. We only have one more call in 2022 in Nov. Drug has to be approved and launch prep takes while after that too.
Again, info we have been given on Dexcel has only hinted at down road and nothing soon. Government agencies take forever in making decisions, this is no exception.
Do you listen to the cc’s?
Elite currently doesn’t sell product in Israel and is unlikely to this calendar year.
Not exactly. He has been getting paid through his non-arms length deals with Elite via Mikah.
Board hasn’t been paid for while.
Yes, corrected myself. Ironic thing is I used to be a treasury consultant and help companies avoid bankruptcy…
“There was no news”. Lol
AI written article on standards technicals only.
Typed too fast. Ch 11 is reorg. Ch 7 is liquidation. They’ll go Ch 11 route.
Chapter 7 is reorg. They aren’t liquidating. Big difference.
They are making headway on bio similar insulin glagine, which is massive.
In a shortage with flat sales quarter over quarter?
Not a chance at this stage
Lol it was extended until March 2024 and then Lannett changed their mind and cut it short. Nice try.
We have a board politician. Nice cowboy math shooting from hips.
Wonder how Vigabatrin launch is going with Lannett?
Lannett’s not terminating what?
Loan would be collateralized with Elite’s, not Mikah’s assets. Funny how that would work out.
because he saw the writing on the wall…
Now we are in the dark until November call with probably no update until then. Uncertainty is king with Elite. Get ready for a walloping.
I remember the Friday post-close news of SequestOx. This is a close 2nd place.
It has taken Elite several YEARS to bring in today’s Adderall revenue, not a few months. This was my biggest fear with Elite. They rushed to get loan before losing Lannett deal as they knew there was serious risk. I’m certain they will max this out for cash flow purposes. They will not be CFP after Lannett deal terminates, which means LPC IV?
These drugs won’t ramp enough and replace Adderall revenue. This is going to cause some serious, serious pain.
Nope, just as suspected. Elite’s back is against the wall yet again. This is a Friday disclosure after market close for a reason.
I can buy XR in my geography for ~$20 retail price for month supply of 5mg.
Funny how many times shares can be sold out by a shareholder.
He should be. The 2 Adderall products produce most of Elite’s revenue.
They haven’t discontinued the Adderall IR ANDA that they own, but they did with Adderall XR.
Sadly it doesn’t mean Elite has either the contract or API approved for more volume.
They lowered their FY sales estimate once again.
I can assure you Bill was no great leader during his Cleveland coaching years.
You are missing one. He stopped trying to partner with Codeine after no one would. That ANDA was funded and hit a wall after approval. Can’t even sell it off.